The role of anti-IgE therapies in the treatment of asthma.
The prevalence of asthma, a chronic inflammatory disease often linked to allergy, is on the increase. The introduction of a blocking anti-IgE monoclonal antibody (omalizumab) as a new therapy has not only confirmed the pathogenic role of IgE in asthma but has also provided a novel therapy for a chronic severe disease where there are limited therapeutic options.